AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 282 min read$IQV

IQVIA Holdings Inc (IQV) (Q3 2026) Earnings Call Highlights: Record Bookings, Raised

IQVIA Holdings Inc. reported Q3 2026 earnings with record bookings and raised guidance. Revenue was $4.428B, up 8% YoY, and adjusted EBITDA rose 8.7%. Challenges include FX headwinds and R&D backlog adjustments. Management highlighted AI adoption and strong biotech demand. Full-year 2026 guidance was increased, with revenue expected between $17.35B-$17.5B. No 2027 guidance was provided.

Original reporting
finance.yahoo.com
Published Oct 28, 2026, 7:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 7:03 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
IQVIA Holdings Inc (IQV) (Q3 2026) Earnings Call Highlights: Record Bookings, Raised — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$IQVBullishMed
01

Why it matters

The guidance upgrade is a fresh, material development that can drive short‑term price appreciation; margin headwinds may temper longer‑term gains.

02

Market read

First report of IQVIA's raised 2026 guidance; provides a clear catalyst for traders to consider positioning in IQV.

03

What to watch

Backlog adjustment of $2.1 bn signals potential quality concerns; net leverage of 3.45× may constrain future financing.

Relevance 8/10Novelty 8/10Timing: immediate reaction post‑earnings call

Background

IQVIA's Q3 2026 earnings call highlighted record bookings, AI integration, and a raised full‑year outlook, while noting margin pressures from pass‑throughs and currency.

Company-level read

Ticker impact

$IQVBullishHigh confidence
Context

IQVIA raised its full‑year 2026 revenue guidance to $17.35‑$17.50 bn and adjusted EBITDA to $4.025‑$4.055 bn after reporting record Q3 bookings and EPS beat.

Expected impact

likely upward pressure as investors price in higher revenue and earnings outlook

Evidence & confidence

Guidance lift is material and new; market typically reacts positively to earnings‑beat and guidance upgrades.

Market effects

Sector

Strengthens outlook for the health‑care services and CRO sector, supporting peers with similar business models.

Regional

Positive for U.S. biotech and pharma service providers, modest spillover to European markets where IQVIA sees growth.

Global

Reinforces confidence in AI‑enabled health‑data platforms globally.

Counterpoint

What could challenge this read

The guidance lift may already be priced in; margin headwinds from pass‑throughs and FX could limit upside.

Key entities

  • Executive
    Ari Bousbib

    IQVIA CEO who discussed AI strategy and raised guidance.

  • Executive
    Mike Vidhop

    IQVIA CFO who detailed margin dynamics and net interest expense.

Read at source← All news

StoryIQVIA reports Q3 2026 beat and lifts full‑year revenue and EPS outlook

Also covered by

5 outlets

Related articles

OCT 27
$IQVHighAI 8/10

What IQVIA (IQV) Said on Its Q3 Earnings Call

IQVIA reported Q3 revenue growth of 6.9% to $1.79B, with organic growth at 4%. AI adoption contributed to commercial and clinical momentum, with 415 AI agents deployed. The company raised its 2026 outlook, expecting revenue of $17.35B-$17.50B and adjusted EPS of $12.90-$13.00. Cash flow from operations was $825M, with free cash flow at $667M.

finance.yahoo.com2 min
OCT 27
$IQVHighAI 9/10

IQVIA (IQV) Q3 2026 Earnings Call Transcript

IQVIA reported Q3 2026 revenue of $4.43B, up 8%, with organic growth at 6%. Adjusted EBITDA grew 8.7% to $1.03B, and adjusted EPS rose 11.3% to $3.34. R&D solutions revenue increased 8.7%, and commercial solutions revenue grew 6.9%. The company raised full-year revenue guidance to $17.35B-$17.5B. AI deployments and emerging biopharma funding growth were highlighted.

fool.com2 min
OCT 27
$IQVHighAI 8/10

IQVIA Holdings Inc. Q3 2026 Earnings Call Summary

IQVIA Holdings Inc. reported Q3 2026 organic revenue growth of 6%, driven by clinical segment momentum and AI integration. The Emerging Biopharma segment saw record demand with $90B funding YTD. Full-year guidance was raised, with AI expected to support future margin expansion. Management highlighted competitive advantages through AI and strategic partnerships. Q4 interest expense is projected at $210M. A $2.1B backlog scrub was conducted to improve visibility.

finance.yahoo.com3 min